CD40 Ligand Mutants Responsible for X-linked Hyper-IgM Syndrome Associate with Wild Type CD40 Ligand

• Published in: The Journal of biological chemistry 1999-04, Vol.274 (16), p.11310-11320
• Main Authors: Seyama, K, Osborne, W R, Ochs, H D
• Format: Article
• Language: English
• Subjects: Animals; Base Sequence; CD4-Positive T-Lymphocytes - immunology; CD40 Ligand; Cell Membrane - immunology; COS Cells; DNA Primers; Genetic Linkage; Hypergammaglobulinemia - genetics; Hypergammaglobulinemia - immunology; Immunoglobulin M - blood; Membrane Glycoproteins - genetics; Mutation; Precipitin Tests; RNA Splicing; Syndrome; X Chromosome
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.274.16.11310

CD40 ligand (CD40L) is a 33-kDa type II membrane glycoprotein mainly expressed on activated CD4 + T cells in trimeric form. When it is mutated, the clinical consequences are X-linked hyper-IgM syndrome (XHIM), a primary immunodeficiency disorder characterized by low levels of IgG, IgA, and elevated or normal levels of IgM. Mutated CD40L can no longer bind CD40 nor provide signals for B cells to proliferate and to switch from IgM to other immunoglobulin isotypes. When considering gene therapy for XHIM, it is important to address the possibility that the mutated CD40L associates with transduced wild type CD40L, and as a consequence, immune reconstitution is not attained. In this study, we demonstrate that the various mutated CD40L species we have identified in patients with XHIM, including both full-length and truncated mutants, associate with wild type CD40L on the cell surface of co-transfected COS cells. The association between wild type and mutated CD40L was also observed in CD4 + T cell lines established from XHIM patients with leaky splice site mutations. The clinical phenotype of these patients suggests that this association between wild type and mutated CD40L species may result in less efficient cross-linking of CD40.